Although erythropoietin (Epo) is commonly used as a therapy for anemia, recent studies have suggested that Epo therapy is associated with adverse outcomes. A new study shows that polymeric IgA1 ...
Background: Erythropoiesis-stimulating agents are used to treat anemia in patients with cancer. However, their safety and effectiveness is controversial. We did a systematic review of the clinical ...
The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and ...
Please provide your email address to receive an email when new articles are posted on . Anemia in patients with cancer can be caused by a number of factors including blood loss, hemolysis, nutritional ...
Effects of bendamustine, bortezomib, and rituximab on 1-year survival rates in elderly patients newly diagnosed with mantle cell lymphoma. This is an ASCO Meeting Abstract from the 2018 ASCO Annual ...
Two hundred-billion red blood cells are renewed in our body every single day. These erythrocytes (also known as red blood cells) are generated from bi-potent megakaryocyte-erythroid progenitor cells ...
Anemia of inflammation (also referred to as anemia of chronic disease) has been recognized for more than 60 years as a mild to moderately severe anemia (hemoglobin level, 7 to 12 g per deciliter) that ...
We investigated whether a novel, synthetic, peptide-based erythropoietin-receptor agonist (Hematide, Affymax) can stimulate erythropoiesis in patients with anemia that is caused by antierythropoietin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results